PRPH prophaselabs.com: Enterprise Value to Sales Volume

prophaselabs.com (PRPH) - corporate logo

The integration of Nebula Genomics AI platforms with laboratories creates a closed-loop diagnostic cycle, driving the search for new genetic revenue streams as COVID-related volumes decline for ProPhase Labs, Inc. (PRPH). This EV/Sales valuation chart clearly confirms this transformation, with the value holding at 0.00. The picture is completed by the outsourcing of biomaterial logistics and IT services to third-party contractors to optimize cloud platforms.

ProPhase - PRPH EV/Sales Multiple (period 11/23/2025 - 01/10/2026)

prophaselabs.com - analytical breakdowns and key metrics (PRPH)

- price and consensus price forecast:
- company stock capitalization data:
Fundamental valuation:prophaselabs.com PRPH
Original product of ProPhase Labs, Inc.

This metric combines market capitalization and net debt, comparing the total enterprise value to sales volume to determine the actual price of one dollar of revenue. As ProPhase Labs, Inc. (PRPH) hedges against US geopolitical risks, the EV/Sales chart serves as an indicator of operational model efficiency, allowing investors to assess the quality of asset management regardless of the financing structure.

Competitor analysis

A (Agilent) - Company Value to Revenue Ratio|DGX (Quest Diagnostics) - Company Value to Revenue|Illumina Inc (ILMN) - EV/Sales Multiple|Company Value to Revenue EXAS|Revvity, Inc. (RVTY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple BIO|NNNN (Anbio Biotechnology) - Business Value to Revenue|EV/Sales Multiple SHC (Sotera Health)|Quidel Corporation (QDEL) - Enterprise Value-to-Revenue Multiple|OPK - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio CareDx Corp CDNA|Maravai LifeSciences (MRVI) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Sales Ratio Fulgent Genetics, Inc. FLGT|LAB (Standard BioTools Inc) - EV/Sales Multiple|Cytek Biosciences (CTKB) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple OSUR|Exagen - Company Value to Revenue Ratio|EV/Sales Multiple MDXH (MDxHealth, Inc.)|luciddx.com (LUCD) - Enterprise Value-to-Revenue Multiple|prenetics.com - EV/Sales Multiple|Insight Molecular Diagnostics, Inc. (IMDX) - Company Value to Revenue|TRIB: EV/Sales Multiple|Company Value to Revenue Ratio AIMD|Company Value to Revenue CODX|Enterprise Value-to-Revenue Multiple heartsciences.com HSCS|Enterprise Value-to-Revenue Ratio Biomerica Inc. (BMRA)|Total Company Value-to-Revenue Ratio Cardio Diagnostics Holdings|EV/Sales Multiple ONCO (Onconetix Corporation)|Virax Biolabs Group (VRAX) - Enterprise Value-to-Revenue Multiple|bluejaydx.com - EV/Sales Multiple|Aspira Women's Health - Enterprise Value-to-Revenue Coefficient|AXDX (Accelerate Diagnostics) - Company Value to Revenue|Company Value to Revenue CENTOGENE, N.V.|Enterprise Value-to-Revenue Ratio enzo.com|EV/Sales Multiple Fresh2 Group Limited|EV/Sales Multiple GENE|23andMe Holding Co. - Company Value to Revenue Ratio|Psychemedics Inc - Company Value to Revenue